# CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

> **NCT04318678** · PHASE1 · RECRUITING · sponsor: **St. Jude Children's Research Hospital** · enrollment: 108 (estimated)

## Conditions studied

- AML/MDS
- B-ALL
- T-ALL
- BPDCN

## Interventions

- **DRUG:** CD123-CAR T
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Mesna
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT04318678
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-29
- **Primary completion:** 2029-07-29
- **Final completion:** 2030-07-29
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04318678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04318678, "CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04318678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*